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Abbreviations  
BCAM: Basal Cell Adhesion Molecule (carries Lutheran blood group system antigens) 
CDA: Congenital Dyserythropoietic Anaemia  
CD44: CD44 antigen glycoprotein (carries Indian blood group system antigens) 
GATA1: GATA Binding Protein 1 
IN: Indian blood group system 
In(Lu): Inhibitor of Lutheran (phenotype) 
ISBT: International Society of Blood Transfusion 
KLF1: Erythroid-specific Krüppel-like factor 1 
KN: Knops blood group system 
LU: Lutheran blood group system 
LW: Landsteiner‐Wiener blood group system 
RBC: Red Blood Cell 
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Abstract 
Erythroid-specific Krüppel-like factor 1, or KLF1, is an integral transcriptional activator for 
erythropoiesis. Genetic variants within KLF1 can result in a range of erythropoietic clinical 
phenotypes from benign to significant. The In(Lu) phenotype refers to changes in the quantitative 
expression of blood group associated red cell surface molecules due to KLF1 variants which are 
otherwise clinically benign.  
These clinically benign KLF1 variants are associated with a reduced expression of one or more red 
cell membrane proteins/carbohydrates that carry blood group antigens for the LU (Lutheran), IN 
(Indian), P1PK, LW (Landsteiner‐Wiener), KN (Knops), OK, RAPH and I blood group systems. This is of 
significance during routine serologic blood typing when expression falls below the test sensitivity 
and therefore impacts on the ability to accurately detect the presence of affected blood group 
antigens. This is of clinical importance since the transfusion requirements for individuals with the 
In(Lu) phenotype differ from those of individuals that have a true Lunull phenotype. With this review 
we summarise the current body of knowledge with regard to the In(Lu) phenotype and associated 
KLF1 variants. Our review also highlights discordant reports and provides insights for future research 
and management strategies.  
Serological heterogeneity in blood group expression of In(Lu) individuals has been shown, but 
studies are limited by the low prevalence of the phenotype, and therefore the small numbers of 
samples. They are further limited by availability and inconsistent application of serological reagents 
and varying tes algorithms. With the advent of genome sequence-based testing, an increasing list of 
In(Lu) associated KLF1 variants are being revealed.  The spectrum of effects on blood group 
expression due to these variants warrants further attention and a consistent methodological 
approach of studies in larger cohorts is required.   
We propose a recently reported testing framework of standardised serological studies, flow 
cytometry and variant analysis be adopted; and that the international databases be curated to 
document KLF1 variability and the resultant In(Lu) red cell blood group expression.  This will provide 
better classification of KLF1 variants affecting blood group expression and allow for phenotype 
prediction from genotype, accurate typing of In(Lu) individuals, and better transfusion management 
of related challenging transfusion scenarios. 
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Introducing erythroid-specific transcription factor, KLF1  
Cellular differentiation is a genetically driven process involving activation of an array of genes and 
pathways within each distinct tissue type. An integral transcriptional activator in the pathway of 
progenitor cells committing to erythropoiesis is erythroid-specific Krüppel-like factor 1, or KLF1.  
Initially referred to as EKLF, KLF1 was discovered from murine-based studies in 1993 [1] and our 
understanding of the significance for KLF1 in human erythropoiesis has progressed over the last 10 
years; elucidated from serologic, genomic and transcriptomic studies [2, 3]. 
In humans, the KLF1 protein is a product of the KLF1 gene, it being located on chromosome 19 and 
composed of three exons and two introns [4]. The translated 362 amino acid protein contains two 
transactivation domains at the N-terminal of the protein and three zinc fingers at the C-terminal [3] . 
These highly conserved zinc fingers come into contact with DNA at 9bp motifs which conform to the 
degenerate motif, CCMCRMCCN; where M=C or A,  R=A or G and N=any base [1]. KLF1 thereby 
regulates the activity of over 650 erythropoietic genes [5]. It is therefore unsurprising that genetic 
variants within KLF1 can result in a range of erythropoietic phenotypes; from clinically insignificant 
morphological changes up to clinically significant and pathologic conditions.  
The frequency of KLF1 variants can range from 0.0004% to 37%, varying in different global 
geographical locations [6-8]. This includes common and rare variants, with or without a clinically 
significant consequence. KLF1 genetic variants have been stratified from class 1 to 4 according to the 
clinical phenotype which is related to the variant type, its location within the gene and the 
consequence on the transcribed protein [3].  Class 1 variants are mostly neutral polymorphisms. An 
example being the p.Ser102Pro variant which occur at a frequency of 37% in the Genome 
Aggregation Database (gnomAD) and is known to not impact on blood group antigen expression [8, 
9]. Class 2 variants are the most interesting in terms of unpredictable phenotypic impact. They are 
missense variants in the DNA-binding domain and result in protein variants with reduced or 
sometimes altered DNA-binding affinities. However, these tend to be less phenotypically severe than 
loss of function variants, i.e. class 3 where stop codon or frameshift variants result in truncated 
proteins that lack the DNA-binding domain. Class 4 is reserved exclusively for an alteration of a 
highly conserved residue (p.Glu325Lys) in the DNA-binding domain which causes dominant and 
pathogenically severe Congenital dyserythropoietic anaemia (CDA) type IV [3]. KLF1 variants in 
classes 2 to 4 are not compatible with life at a homozygous level and are therefore detected at a 
heterozygous level in individuals, as reflected in gnomAD [8].  We note one interesting reported case 
of severe neonatal anemia with kernicterus due to compound heterozygosity for class 3 variants 
[10].  
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The primary focus of this review will be the KLF1 class 2 and 3 variants which are not known to be 
associated with pathogenic clinical manifestations at a heterozygous level.  Although otherwise 
considered clinically benign, these variants do still cause reduced expression of one or more red cell 
membrane proteins that carry blood group antigens to give what is now called the In(Lu) phenotype 
(see next section). This impacts on the ability to accurately detect the presence of affected blood 
group antigens by routine serologic blood typing, as expression falls below the test sensitivity. This 
review focuses primarily on those variants that have been described in blood group screening 
studies, performed on the blood of healthy blood donors.  We summarise historical findings 
attributed to KLF1 variants affecting blood group antigens, which reveal a possible spectrum of 
phenotypes even within the class 2 and 3 KLF1 variants.   
 
The In(Lu) phenotype and clinical significance 
The classic example for the impact of the class 2 and 3 KLF1 variants is for the Lutheran system (LU), 
designated ISBT 005 [9]. The Lutheran blood group system is known to comprise at least 25 blood 
group antigens which are carried on two isoforms of the red cell membrane glycoprotein which is 
termed Basal cell adhesion molecule (BCAM). Lutheran antigens show variable antigenic strength, 
even within families and even between red cells of an individual [11, 12].   
Polymorphisms in the BCAM gene define the LU blood group antigens, e.g. the primary antithetical 
antigens Lua and Lub. Homozygous inactivating variants result in the recessive Lunull phenotype, Lu(a–
b–) [11, 13]. In contrast, class 2 and 3 KLF1 variants cause an apparent dominantly inherited Lu(a–b–) 
phenotype where BCAM expression is reduced to such an extent that LU antigens are difficult to 
detect by agglutination methods. Other than KLF1, GATA Binding Protein 1 (GATA1) is another 
transcription factor that has been implicated in an apparent Lu(a–b–) phenotype. In this case, a 
hemizygous variant in the X-linked GATA1 gene leads to serological characteristics of both the 
recessive Lu(a–b–) and In(Lu) phenotypes [14, 15]. Determining the cause of apparent loss of LU 
antigens is beneficial for transfusion management. 
For accurate blood group typing, it is important to determine whether red cells that are presenting 
with an apparent phenotype of Lu(a–b–) are a true Lunull phenotype. Although very rare, Lunull 
individuals have been detected by their development of anti-Lu3, thereby requiring transfusion of 
antigen-negative red cells [13]. In contrast, it is not necessary to transfuse patients with the In(Lu) 
phenotype with Lunull red cells, as such patients are not at risk of being alloimmunised if transfused 
with matching Lutheran typed red cells.  Given that Lunull red cells are rare, this ensures that such 
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donations can be reserved for patients with true Lunull phenotypes. Paradoxically, there is evidence 
to suggest that red cells with the In(Lu) phenotype can be provided to patients with the Lunull 
phenotype as the weakened antigen expression reduces the risk of alloimmunisation in the non-
matched recipient [16].  
Red cells with the In(Lu) phenotype are also of particular importance during transfusion 
management of individuals that have developed anti-AnWj antibodies (AnWj antigen discussed in 
subsequent section on phenotypic effect of In(Lu)). For these individuals, providing AnWj-negative 
red cells for transfusion is challenging and the physiological responses in such patients are variable: 
some individuals suffer no adverse effects when transfused incompatible units [17, 18], while others 
have been affected by severe red cell haemolysis [19].  As AnWj-negative red cells are extremely 
rare, In(Lu) blood has been safely substituted to meet transfusion requirements [19].  
 
History of In(Lu) discovery 
It was the apparent loss of expression of both the Lua and Lub in the Lutheran blood group system 
that resulted in the first study of the In(Lu) phenotype.  This occurred in 1961, when 
immunohematologist Dr Mary N. Crawford serendipitously discovered that her own red cells 
appeared to phenotype as Lu(a–b–). This apparent phenotype was also detected across three 
generations of her family and Dr Crawford gave the first description of a dominant inheritance for 
this apparent Lu(a–b–) phenotype [20] . Further testing of these serologically Lu(a–b–) red cells by 
laborious adsorption and elution techniques demonstrated that these cells actually do express the 
Lua and/or Lub antigens, albeit very weakly, therefore raising the suggestion of an inhibition to their 
full expression.  Thereby, this characteristic marked reduction, but not loss, in Lutheran antigens, 
was termed the In(Lu) phenotype, an abbreviation of Inhibitor of Lutheran [21].  While investigating 
the original Lu(a–b–) phenotype, Dr Crawford also identified suppression of the P1 (P1PK blood 
group system) antigen [22]. Over the next 11 years, similar observations were identified in other 
families displaying comparable Lu(a–b–) inheritance and serological patterns [23, 24].  
Other phenotypic effects of In(Lu) 
From further findings in the early 1980s, it was accepted that corresponding reduction of another 
red cell antigen occurred alongside the In(Lu) phenotype.  This antigen was studied under various 
names including p80 (based on its size), A3D8 antigen (based on monoclonal antibody reactivity) and 
Pgp-1 (phagocytic glycoprotein-1) [14].  Convergence of knowledge now has this glycoprotein 
structure known as CD44, which carries the Indian (IN) blood group system [14, 15].  Historical 
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serological evidence indicates that CD44 expression is similar between the In(Lu) members of the 
same family but dissimilar compared to other families [25]. The combination of serologic Lu(a–b–) 
and reduced CD44 is a hallmark of the In(Lu) phenotype and is consistent for KLF1 class 2 and 3 
variants [2, 26-28]. This insight has allowed for the use of anti-CD44 antibodies in mass-screening 
exercises to identify potential In(Lu) individuals [26, 29-33].    
Historic serology studies also established that the In(Lu) phenotype is further characterized by 
reduced expression of the high frequency antigen called AnWj, thought to be located on the CD44 
glycoprotein. AnWj is also decreased on In(Lu) cells [18] and it has been known since 1991 that the 
genetic locus for this antigen is not linked to the LU blood group system [34]. The AnWj-negative 
phenotype has recently been linked to a missense mutation in the SMYD1 gene based on genetic 
and statistical evidence, however, functional proof is still required. The SMYD1 protein is proposed 
to act as a transcription factor during early erythropoiesis but the underlying mechanism leading to 
the loss of AnWj remains unresolved [35].  
Other than the characteristic blood group profiles described above, historic serology studies provide 
evidence that red cells with the In(Lu) phenotype may also have reduced or altered expression of 
other blood group antigens in the P1PK, LW (Landsteiner-Wiener), KN (Knops), OK, RAPH and I 
systems (Table 1) . For the P1PK system, the A4GALT transferase produces both P1 and Pk antigens 
[36], but only P1 is impacted to variable degrees [22, 27, 32, 37]. This suggests that KLF1 may not 
directly target A4GALT but may act on a transferase that produces Lactotriaosylceramide or 
Paragloboside which are precursors of the P1 antigen in the paragloboside series [22, 38, 39].  
For the LW system, the impact of KLF1 variants on LW antigen expression has not only been 
demonstrated in In(Lu) RBCs [28, 40], but also appears to be reflected in CDA where an associated 
LW(a–b–) phenotype is caused by the single class 4 KLF1 variant, p.Glu325Lys [41].   
The findings reported for the KN Blood Group system are ambiguous and may not only be caused by 
the specific underlying KLF1 variants, but also genetic differences in CR1 such as the H/L haplotypes 
associated with high and low CR1 copy numbers [12, 28, 42]. For the OK system, our recent study of 
In(Lu) in  Australian blood donors suggests that the BSG transcription rate changes observed in 
cultured In(Lu) erythroblasts in the ground-breaking 2008 Singleton study (see next section) may 
also be observable on mature erythrocytes [2, 28]. For the RAPH system, findings from a family study 
in the 1980’s suggested that the In(Lu) phenotype slightly decrease the expression of the MER2 
antigen [43]. Finally for the I system, serological investigations in the 1970’s and 80’s reported 
reduced levels of the i antigen on In(Lu) RBCs compared to normal adult cells [10, 31]; the latter 
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study also reported a slight associated increase in I antigen. The mechanism behind these 
observations is unclear, however the reduction of neighbouring structures associated with In(Lu) 
may allow the antibody better access to the antigen, thus producing an increased level of binding. 
Despite these reports, studies have been thwarted by the low prevalence of In(Lu), small numbers of 
samples and variable application of serological reagents and/or testing algorithms, admittedly also 
due to the availability of reagents at that point in history.   
 
The In(Lu) phenotype is linked to variants in KLF1 
From Dr Crawford’s first description of the In(Lu) phenotype, it was another 47 years until the 
causative gene locus was identified to be KLF1 [2, 20].  In 2008, Singleton and colleagues achieved 
this by observing the transcriptome of cultured erythroblasts from four In(Lu) phenotype blood 
donors, comparing these to control erythroblasts. At incremental stages of maturation, differences 
in transcription rates were observed between the two groups, leading the team to hypothesize that 
a mutated erythroid transcription factor was the cause of this pattern of results. Sequencing 
performed on 24 archived In(Lu) phenotype samples revealed 21 of the 24 samples to have 
heterozygous variants in the KLF1 gene.  Nine different loss-of-function variants in KLF1, that results 
in reduced or abolished protein function, were described from these samples [2]. This confirmed 
that the serological phenotype is caused by erythropoietic suppression of antigen expression during 
red cell development, rather than by the action of a dominantly inherited inhibitor gene as 
previously hypothesized [2]. The study also identified that there is more than one KLF1 variant that 
can result in an In(Lu) phenotype; but does not address any variability within the phenotype caused 
by each variant. 
 
Population studies on the In(Lu) phenotype and KLF1 variants 
With the discovery that the transcription factor KLF1 impacts on blood group phenotypes, 
genotyping for KLF1 variants became an important part of investigations into the In(Lu) phenotype. 
Population studies in this field have however been few in number.  
The first retrospective study in 2012 was conducted on historic samples in the rare blood collection 
at the French National Reference Centre for Blood Groups and pioneered the use of flow cytometry 
analysis to confirm In(Lu) [26]. The group identified 10 causative KLF1 variants, (seven novel) in 10 
propositi samples. A more recent study in 2017 investigated the In(Lu) phenotype in American 
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patients and blood donors. Interestingly, this study included a stored sample from the Crawford 
index case and showed that this first In(Lu) phenotype arose from heterozygosity for the 
KLF1*BGM06 allele where a nucleotide change NM_006563.3:c.954dupG  predicts the 
p.Arg319Glufs*34 [27]. This study did not, however, follow suit in using flow cytometry to confirm 
In(Lu) but relied on serological testing by standard tube methods.   
We recently conducted the first population screening within Australia and identified the In(Lu) 
phenotype in four out of 8036 Queensland blood donors (frequency = 1 in 2,009) [28]. These four 
samples, and two additional historical In(Lu) samples, were analysed further. Our approach included 
serological screening to identify negative or very weak Lu serology, sequencing to identify KLF1 
variants and comprehensive flow cytometric analysis of RBC proteins (n=14) and surface 
carbohydrates (n=6). Through this approach we identified five different KLF1 variants (two novel) in 
the six samples.  
As expected from such a rare phenotype, all of the above mentioned studies were limited by the 
number of In(Lu) samples included. Although each study identified several KLF1 variants, analysis of 
the phenotypic impact of these variants were mostly limited to the LU, IN and P1PK systems in the 
retrospective studies. Even with the small number of In(Lu) samples analysed, Keller et al did note 
the variable impact of KLF1 variants, consistent with the KLF1 variant classes as defined by Perkins et 
al in 2016 [3, 27].  In our study of an Australian blood donor population, our testing algorithm 
allowed us to further identify variability even within the In(Lu) phenotype [28].  
 
 
KLF1 variants listed with curated Blood Group Allele Tables 
All reported KLF1 variants known to impact on blood group antigen expression are registered on the  
allele nomenclature tables, curated and maintained by the International Society of Blood 
Transfusion (ISBT) working party for Red Cell Immunogenetics and Blood Group Terminology [9]. The 
current ISBT listing shows at least 65 KLF1 variants that have been associated with altered blood 
antigen expression and these, as well as others which are under review, are summarised here in 
Table 2. Because KLF1 variants are so rare, only a few are represented in international databases 
such as gnomAD. The frequency and coding region location of these variants are presented in Figure 
1. 
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The original study by Singleton et al. from the Bristol Institute for Transfusion Sciences defined the 
first nine allelic variants in the Table. These are designated KLF1*BGM01 to 09. The next variant 
listed on the Table was detected in individuals with the severe CDA type IV [25]. This is the 
NM_006563.3:c.973G>A change which defines the KLF1*BGM10 allele and predicts a p.Glu325Lys 
substitution. Interestingly the individuals with this KLF1*BGM10 allele may not have an altered 
Lutheran phenotype but do have reduced expression of CD44, AQP1 (Colton system) and ICAM4 [40, 
41].  With the exception of KLF1*BFM10, all other listed variants are associated with the In(Lu) 
phenotype, having reduced expression of Lutheran blood group antigens.  
 
 
 
 
Summary and conclusion 
In summary, the historical serology evidence indicates that KLF1 variants impact on the expression of 
molecules carrying red cell antigens other than just for Lutheran and Indian systems. Serological 
heterogeneity observed for these blood group systems lead us to hypothesise that the impact on red 
cell antigen expression may be dependent on the exact KLF1 variant. More specifically that some 
blood group molecules (such as BCAM and CD44) will be impacted by most KLF1 variants while other 
blood group molecules (such as CR1) may only be impacted by a particular KLF1 variant. 
The spectrum of effects on blood group expression due to these variants warrants further attention. 
With the advent of genomic sequence-based testing, studies into KLF1 variants have already 
revealed an array of alleles and this list is expected to increase [9]. A consistent methodological 
approach of studies in larger cohorts is required to correlate these KLF1 variants with particular 
phenotypical changes.   
We propose the testing framework of standardised serological studies, flow cytometry and variant 
analysis adopted in Fraser et al [28], and that an international database be established/curated to 
document variability to enable accurate prediction of the resultant In(Lu) red cell blood group 
expression from genotype.  This will provide better classification of KLF1 variants affecting blood 
group expression, accurate typing of In(Lu) individuals, and better transfusion management of 
related challenging transfusion scenarios. 
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Figures 
 
Figure 1. Comparison of the gnomAD allele frequencies for 18 In(Lu)-associated KLF1 alleles. 
Only 18 of the 65 In(Lu)-associated KLF1 alleles currently listed by the ISBT have allele frequency 
data available on gnomAD. The allele frequencies for these 18 alleles are presented in the upper 
lollipop plot section in order of CDS position (LRG sequence: NG_013087.1). Class 2 and 3 variants 
(as defined by Perkins et al. 2016) are violet and turquoise lollipops, respectively. Allele names 
associated with each lollipop are shown as grey italic text.   The lower horizontal barplot shows CDS 
regions that are encode KLF1 functional domains. TAD = transactivation domain; ZF = zinc finger. 
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Tables 
Table 1: Summary of blood group systems, other than Lutheran (LU) and Indian (IN), reported to have altered antigen expression associated with the In(Lu) 
phenotype 
ISBT 
number 
Blood 
Group 
System 
Gene 
Name 
Gene Product Gene Product Role 
in Antigen 
Presentation 
Reported Impact 
of In(Lu)  
Research Study(ies) 
3 P1PK A4GALT Lactosylceramide 4-
alpha-
galactosyltransferase 
(A4GALT) 
Enzyme that 
synthesizes P1 and 
Pk antigens on 
paragloboside & 
lactosylceramide 
respectively. 
↓ P1 antigen  
 
 
Crawford et al., 1974 [22] 
Serological investigation identified lack (suppression) of 
P1 antigen in 43 samples with dominant Lu(a–b–) type; 
52 non Lu(a–b–) samples had P1/P2 distribution 
expected in general population.  
Shaw et al., 1984 [37] 
Family studies where serological investigation found the 
P1/P2 distribution in 45 dominant Lu(a–b–) samples to be 
different  from that of 34 non Lu(a–b–) samples. Family 
tree analysis shows suppression of P1 in one family.  
Kawai et al., 2017 [32] 
Serological investigation and genotyping identified 29 
In(Lu) samples with significantly weakened P1 
expression.  
Keller et al., 2018 [27] 
Serological investigation and genotyping for seven 
In(Lu) case studies identified weakened P1 expression in 
one historical sample from 1961.  
16 LW ICAM4 Intracellular 
adhesion molecule 4 
(ICAM4) 
Single-pass RBC 
membrane 
glycoprotein 
carrying the LW 
antigens 
↓ ICAM4 protein 
 
Singleton et al., 2011 [40] 
Promotor binding experiments using recombinant 
forms of wild type and KLF1 mutants identified 
weakened expression of ICAM4.   
Fraser et al., 2018 [28] 
Flow cytometric analysis and genotyping identified 
reduced ICAM4 levels on the surface of In(Lu) RBCs 
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from Australian blood donors.  
22 KN  CR1  Complement 
receptor type 1 
(CR1) 
Single-pass RBC 
membrane 
glycoprotein 
carrying the KN 
antigens 
↓ Kna, Kna-like, 
Sla, McCa and Yka 
antigens 
Daniels et al., 1986 [42] 
Antibody titration analysis for dominant Lu(a–b–) and 
non Lu(a–b–) samples in 12 families. Reduced 
expression of Kna, Kna-like, Sla and McCa observed (to 
varying degrees) in all In(Lu) sample; reduced 
expression of Yka observed in most cases. 
No impact Moulds et al., 1999 [12] 
Serological investigation, genotyping and 
chemiluminescence immunoblotting of nine In(Lu) 
samples showed normal expression of CR1. Results for 
two In(Lu) siblings suggests possible variation within the 
In(Lu) phenotype. Moulds speculates that observations 
made by Daniels study (1986) are due to genetic 
differences in CR1 (possibly the H/L haplotypes) and 
prolonged storage of the RBCs. Moulds data however 
shows poor correlation between CR1 copy numbers and 
H/L haplotyping. 
↓ CR1 protein Fraser et al., 2018 [28] 
Flow cytometric analysis and genotyping identified 
variability in the level of CR1 on In(Lu) RBCs from 
different Australian blood donors. Those with 
decreased levels of CR1 harboured L-haplotype 
associated variants at a heterozygous level; however 
haplotype phasing was not possible. 
24 OK BSG Basigin Single-pass type I 
RBC membrane 
protein carrying 
the OK antigens 
↓ expression of 
BSG 
Singleton et al., 2008 [2] 
Transcriptional analysis of cultured normal and In(Lu) 
erythroblasts identified a -1.7 and -1.3 fold change at 
days six (pronormoblasts) and 11 (normoblasts) 
respectively. 
↓ Basigin protein Fraser et al., 2018 [28] 
Flow cytometric analysis and genotyping identified 
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decreased levels of Basigin on In(Lu) RBCs from 
Australian blood donors; suggests that changes 
observed in erythroblast by Singleton study (2008) may 
also be observed on mature erythrocytes. 
25 RAPH CD151 CD151 antigen Multi-pass RBC 
membrane 
glycoprotein 
carrying a single 
RAPH antigen  
↓ MER2 antigen Garratty et al., 1986 [43] 
Serological investigation using two murine monoclonal 
anti-MER2 antibodies  showed positive reactions for 
seven out of nine dominant Lu(a–b–) samples, i.e. 
strong expression of MER2 on RBCs for majority . 
Additional titration analysis for a large family in which 
In(Lu) was segregating found slightly reduced 
expression of MER2 for  In(Lu) samples. 
27 I GCNT2  N-
acetyllactosaminide 
beta-1,6-N-
acetylglucosaminyl-
transferase 
Converts i antigen 
(dominant in cord 
blood/fetus) to I 
antigen (dominant 
in adults). These 
antigens are 
carbohydrate 
structures situated 
on the interior 
carbohydrate 
chains that present 
antigens for the 
ABO, H and LE 
systems.  
↓ i antigen 
 
Crawford et al., 1974 [22] 
Serological investigation using several anti-i sera found 
very strong reaction with cord cells, much weaker 
reaction with normal adult cells and Lu(a–b–) cells of 
the recessive type and negative/weak reaction with  
In(Lu) cells. 
Shaw et al., 1984 [37] 
Study of 12 families where serological investigation 
using two selected anti-i sera found dramatic 
suppression of i antigen in all In(Lu) individuals whereas 
the I antigen was unaffected. 
 
RBC: red blood cell
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Table 2: KLF1 variants that are presently known to cause the In(Lu) phenotype 
Nucleotide Change† 
Predicted Amino 
Acid Change 
Allele Name¶ Reference 
Variant 
Accession 
Number (dbSNP 
or ClinVar) 
c.-124T>C p.0 KLF1*BGM01 [2] No submission 
c.86A>G p.Lys29Arg KLF1*BGM50 [32] No submission 
c.109C>T p.Gln37X KLF1*BGM39 [32] rs755193431 
c.114delC p.Asp38Glufs*53 KLF1*BGM13 [44] No submission 
c.151delC p.Leu51SerfsX3 KLF1*BGM44 [32] No submission 
c.196G>T p.Glu66X KLF1*BGM40 [32] No submission 
c.199delA p.Gly68AlafsTer236 Not on ISBT yet [45] No submission 
c.204delC p.Gly68GlyfsX169 KLF1*BGM41 [32] No submission 
c.262_284dup p.Ala95AlafsX150 KLF1*BGM51 [32] No submission 
c.298G>T p.Glu100Ter KLF1*BGM14 [44] No submission 
c.304T>C,  
c.484insC 
p.Ser102Pro, 
p.Lys162Glnfs*352 
KLF1*BGM15 [44] 
rs2072597 
rs116107190 
c.304T>C, 
c.1002del2 
p.Ser102Pro, 
p.Thr334Glyfs*351 
KLF1*BGM16 [44] 
rs2072597 
rs764608850 
c.310_311insG p.Ala104GlyfsX249 KLF1*BGM32 [26] No submission 
c.318T>G p.Tyr106X Not on ISBT yet [27] rs956697155   
c.380T>A p.Leu127Ter KLF1*BGM02 [2] No submission 
c.421C>T p.Arg141X Not on ISBT yet [28] rs1426116895 
c.472delG p.Ala158ProfsX79 KLF1*BGM52 [32] No submission 
c.517_519delC p.Pro173ProfsX KLF1*BGM23 [32] rs566095433 
c.519_520insC p.Gly174ArgfsX179 KLF1*BGM33 [26] No submission 
c.519_525dupCGGCGCC p.Gly176ArgfsX179 KLF1*BGM34 [26, 46, 47] rs483352838   
c.533C>A p.Ser178X KLF1*BGM53 [32] No submission 
c.551_556GGA CCG>A p.Gly184GlufsX167 KLF1*BGM24 [32] No submission 
c.569delC p.Pro190Leufs*47 KLF1*BGM03 [2] No submission 
c.591C>G p.Tyr197X KLF1*BGM35 [26] No submission 
c.604G>A p.Gly202Arg Not on ISBT yet [45] rs756658473 
c.621C>G p.Tyr207Ter KLF1*BGM17 [44] No submission 
c.637C>T p.Glu213X KLF1*BGM25 [32] No submission 
c.663delG p.Leu222SerfsX15 KLF1*BGM36 [26] No submission 
c.796C>T p.Arg266X KLF1*BGM42 [32] rs756046932 
c.802C>T p.Arg268X KLF1*BGM26 [32] No submission 
c.809C>A p.Ser270X KLF1*BGM20 [48, 49] rs558942739 
c.826C>T p.Gln276X KLF1*BGM45 [32] No submission 
c.862A>G p.Lys288Glu KLF1*BGM37 [26] No submission 
c.868T>C p.Tyr290His KLF1*BGM46 [32] No submission 
c.874A>T p.Lys292Ter KLF1*BGM04 [2] rs137852687   
c.887T>C p.Leu296Pro KLF1*BGM54 [32] rs754996390 
c.892G>C p.Ala298Pro Not on ISBT yet [49] rs387907598 
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c.895C>T p.His299Tyr KLF1*BGM05 [2] rs137852688   
c.899T>C p.Leu300Pro KLF1*BGM27 [32] rs763096758 
c.902insT p.Arg301LeufsX52 KLF1*BGM28 [32] No submission 
c.90G>A p.Trp30Ter KLF1*BGM11 [42] rs1427628301    
c.911C>A p.Thr304Lys Not on ISBT yet [27] No submission 
c.914-1g>c Splicing failure KLF1*BGM47 [32] No submission 
c.939G>A p.Trp313X KLF1*BGM55 [32] rs1364414353 
c.947G>A p.Cys316Tyr KLF1*BGM29 [32] No submission 
c.948delC p.Cys316Trpfs*326 KLF1*BGM18 [44] No submission 
c.954G>C p.Trp318Cys Not on ISBT yet [28] rs769526751 
c.954dupG p.Arg319Glufs*34 KLF1*BGM06 [2] rs397514445 
c.964C>A p.Arg322Ser KLF1*BGM56 [32] rs376711350 
c.968C>G p.Ser323Trp KLF1*BGM30 [26] No submission 
c.973G>A p.Glu325Lys KLF1*BGM10 [39] rs267607201 
c.977T>G p.Leu326Arg KLF1*BGM21 [26, 49] rs397514634 
c.983G>A p.Arg328His KLF1*BGM08 [2] rs140252918   
c.983G>T p.Arg328Leu KLF1*BGM07 [2] No submission 
c.991C>G p.Arg331Gly KLF1*BGM09 [2] No submission 
c.991C>T p.Arg331Trp KLF1*BGM31 [32, 50] No submission 
c.994A>G p.Lys332Glu KLF1*BGM22 [45] No submission 
c.1001C>T p.Thr334Met KLF1*BGM48 [32] rs483352841 
c.1004G>C p.Gly335Ala KLF1*BGM57 [32] No submission 
c.1012C>T p.Pro338Ser Not on ISBT yet [51] VCV000056892.1 
c.1022G>A p.Cys341Tyr KLF1*BGM43 [32] rs483352839   
c.1040C>A,  
c.1045delT 
p.Ala347Asp, 
p.Ser349Argfs*358 
KLF1*BGM19 [44] No submission 
c.1048C>T p.Arg350Cys KLF1*BGM49 [32] rs1321730417 
c.1071C>A p.His357Gln KLF1*BGM38 [26] VCV000040066.1 
†The table is ordered by Nucleotide Change position (by first change position for multi-variant alleles). 
Nucleotide positions are relative to the LRG transcript sequence, NM_006563.3.  ¶The ISBT allele 
tables are ordered by Allele Name, i.e. in order of discovery and reporting [9]. The KLF1*BGM12 allele 
is also currently listed in the ISBT table but have been found not to be associated with the In(Lu) 
phenotype and this allele is now obsolete.  
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Highlights  
 The variable impact of KLF1 variants on blood group expression is ill-defined. 
 Larger studies are required to enable intra-variant and inter-variant comparisons.  
 A standardised testing framework is proposed to study In(Lu) and KLF1 variants. 
 Current databases need to log variability observed in In(Lu) due to KLF1 variants. 
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